HBV, antivirals, and immunoglobulins after liver transplantation: all that glitters is not gold

Hepatol Int. 2023 Oct;17(5):1324-1325. doi: 10.1007/s12072-023-10499-9. Epub 2023 Mar 2.

Authors

Edoardo G Giannini¹, Quirino Lai²

Affiliations

¹ Gastroenterology Unit, Department of Internal Medicine, University of Genoa, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
² General Surgery and Organ Transplantation Unit, Department of General and Specialty Surgery, Sapienza University of Rome, AOU Policlinico Umberto I of Rome, Viale del Policlinico 155, 00161, Rome, Italy. quirino.lai@uniroma1.it.

PMID: 36862140
DOI: 10.1007/s12072-023-10499-9

No abstract available

Publication types

Letter
Comment

MeSH terms

Antiviral Agents* / therapeutic use
Hepatitis B virus
Humans
Immunoglobulins / therapeutic use
Lamivudine
Liver Transplantation*
Recurrence
Secondary Prevention
Treatment Outcome

Substances

Antiviral Agents
Immunoglobulins
Lamivudine